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Abstract: Coronary artery disease and severe aortic stenosis (AS) often coexist. This study sought
to investigate the impact of normal coronary arteries as negative risk marker in patients undergoing
transcatheter aortic valve implantation (TAVI). Consecutive patients with severe AS undergoing TAVI
were dichotomized according to the presence or absence of normal coronary arteries, defined as absence
of coronary lesions with diameter stenosis ฀30% in vessels ฀1.5 mm in diameter on coronary angiogram
in patients without prior coronary revascularization. The primary end point was 1-year mortality. Out
of 987 patients with severe AS undergoing TAVI, 258 (26%) patients had normal coronary arteries.
These patients were younger, more likely women, and had lower EuroSCORE II and STS risk scores.
Although mortality at 30 days was similar in the normal coronary artery and the coronary atherosclerosis
groups (3.1% vs 5.6%, p = 0.11), it was lower in those with normal coronary arteries at 1 year (8.9%
vs 17%, p = 0.003). In multivariable analysis, the presence of normal coronary arteries on coronary
angiogram independently predicted 1-year mortality (adjusted HR 0.57, 95% CI 0.37 to 0.90, p = 0.02).
In conclusion, this study defined normal coronary arteries as negative risk marker in patients with severe
AS undergoing TAVI.
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Coronary artery disease and severe aortic stenosis (AS) often coexist. This study sought to
investigate the impact of normal coronary arteries as negative risk marker in patients
undergoing transcatheter aortic valve implantation (TAVI). Consecutive patients with
severe AS undergoing TAVI were dichotomized according to the presence or absence of
normal coronary arteries, defined as absence of coronary lesions with diameter stenosis
≥30% in vessels ≥1.5 mm in diameter on coronary angiogram in patients without prior
coronary revascularization. The primary end point was 1-year mortality. Out of 987
patients with severe AS undergoing TAVI, 258 (26%) patients had normal coronary arter-
ies. These patients were younger, more likely women, and had lower EuroSCORE II and
STS risk scores. Although mortality at 30 days was similar in the normal coronary artery
and the coronary atherosclerosis groups (3.1% vs 5.6%, p = 0.11), it was lower in those
with normal coronary arteries at 1 year (8.9% vs 17%, p = 0.003). In multivariable analy-
sis, the presence of normal coronary arteries on coronary angiogram independently pre-
dicted 1-year mortality (adjusted HR 0.57, 95% CI 0.37 to 0.90, p = 0.02). In conclusion,
this study defined normal coronary arteries as negative risk marker in patients with severe
AS undergoing TAVI. © 2020 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/) (Am J Cardiol 2021;143:89−96)
Surgical or transcatheter aortic valve implantation
(TAVI) represent the standard therapy for severe symptom-
atic AS,1-3 as medical options to delay or halt disease pro-
gression do not exist. About half of patients with severe AS
scheduled for TAVI exhibit significant coronary artery
lesions.4−6 Data on the impact of the presence and extent of
coronary artery disease on outcomes after TAVI remain,
however, conflicting and optimal management of coronary
artery disease in terms of timing and completeness of coro-
nary revascularization in the context of TAVI needs to be
determined.7-12 Characteristics and outcomes of patients
presenting with isolated severe AS and normal coronary
arteries have not adequately been investigated. An
advanced understanding of these patients may extend our
knowledge about AS progression and the interplay between
degenerative aortic valve disease and coronary atheroscle-
rosis. This study therefore aims at determining clinical
characteristics and outcomes of patients with severe AS and
normal coronary arteries in a large, prospective cohort of
patients with severe AS undergoing TAVI.
Methods
A total of 987 patients diagnosed with severe AS and
undergoing TAVI at the University Hospital Zurich, Swit-
zerland, between May 2008 and September 2017 were
included in the analysis. Data were prospectively entered
into a dedicated web-based database (REDCap, Vanderbilt
University Medical Center, Nashville), hosted by the Clini-
cal Trial Center at the University Hospital Zurich, Zurich,
Switzerland. Regular follow-up was performed by either
patient visit or phone call or assessed using available hospi-
tal records. Events were categorized according to the
updated standardized end point definitions of the Valve
Academic Research Consortium (VARC)-2 consensus doc-
ument.13 For the purpose of this study, patients were dichot-
omized according to the presence or absence of normal
coronary arteries, with normal coronary arteries defined as
≤30% coronary artery diameter stenosis by visual estima-
tion in at least 2 coronary angiography projections in
patients without prior coronary revascularization, in line
with the European Society of Cardiology working group
position paper on myocardial infarction with non-obstruc-
tive coronary arteries.14 In a sensitivity analysis, patients
were categorized as having normal coronary arteries based
on multi-detector computed tomography (MDCT, absence
of coronary calcium accumulation, Figure 1). The study
was approved by the local ethics committee and performed
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according to the Declaration of Helsinki. Written informed
consent was obtained from all patients.
Transthoracic echocardiography studies were performed
using commercially available ultrasound systems (Philips
iE33 or Epic, Philips Healthcare, Andover, Massachusetts;
GE Vivid 7 or E9 or E95, GE Healthcare, Milwaukee, Win-
cosin). Two-dimensional and Doppler echocardiographic
images were acquired in parasternal long-axis and apical
views and obtained in accordance with the recommenda-
tions of the American Society of Echocardiography and the
European Association of Echocardiography.15 Aortic steno-
sis severity was quantified based on peak jet velocity, mean
transvalvular pressure gradient, and effective orifice area as
calculated by the continuity equation.15,16
Biplane conventional coronary angiography was per-
formed according to current guidelines and standard techni-
ques. Baseline coronary angiograms of all patients were
reviewed by experienced physicians. Normal coronary
arteries were defined as absence of epicardial coronary
artery lesions with a diameter stenosis ≥30% by visual esti-
mation in vessels ≥1.5 mm in diameter in patients without
prior coronary revascularization. Ambiguous results were
assessed using quantitative coronary angiography (QCA,
Xcelera Philips, Eindhoven, The Netherlands).
Multi-detector computed tomography was performed
using a 128-slice dual-source computed tomography system
(Somaton Definition Flash, Siemens Healthcare, For-
chheim, Germany) with the following parameters: a quality
reference tube current time product of 130 mAS/rotation
using automatic tube current modulation (CAREDose; Sie-
mens), a reference tube voltage of 100 kVp using auto-
mated attenuation-based tube voltage selection (pitch 3.2,
gantry rotation time 0.25 s). The reconstructed slice thick-
ness was 0.6 mm with an increment of 0.4 mm using a soft
tissue convolution kernel (Bv36). For image acquisition, a
bolus of 45 mL Iopromide (Ultravist 300, 300 mg/mL,
Bayer Schering Pharma, Berlin, Germany) was injected at a
flow rate of 5 mL/s, followed by a second bolus of 35 mL at
a flow rate of 2.5 mL/s. Then, 60 mL saline solution was
injected at the same flow rate. Bolus tracking in the ascend-
ing aorta was performed with a signal attenuation threshold
of 100 Hounsfield Units at 120 kVp. Coronary arteries with-
out any calcium accumulation and without any wall irregu-
larities were considered as unaffected. The quantification of
aortic valve calcium was performed in a semi-automatic
manner using «calcium scoring» application as previously
described (Syngo.via, Siemens Healthcare, Forchheim,
Germany).17,18
Continuous variables are presented as mean § standard
deviation or median and interquartile range as appropriate,
and categorical variables as number and percentages. The
Shapiro Wilk test was used to test for normality distribu-
tion, and the Levene’s test to assess the homogeneity of var-
iance. Pairwise comparison was performed using the
Student’s t-test or the Mann-Whitney U-test as appropriate.
Categorical variables were analyzed by the Pearson’s Chi-
square test or the Fischer’s Exact test. The probability of
death at one year was calculated using the Kaplan-Meier
method with the Log Rank test used for comparisons among
groups. Cox proportional hazard models were used to assess
independent predictors of death at 1 year. The following
prespecified variables known to be associated with mortal-
ity in AS patients were included in the multivariable mod-
els: age, gender, peripheral artery disease, cerebrovascular
disease, arterial hypertension, type 2 diabetes, dyslipidemia,
overweight and/or obesity (body mass index [BMI] ≥25 kg/
m2), smoking status, chronic obstructive pulmonary dis-
ease, and estimated glomerular filtration rate (eGFR). The
proportionality assumption was assessed by correlation test-
ing based on Schoenfeld residuals. A 2-sided p-value of
0.05 was considered statistically significant. All analyses
were performed with SPSS for Windows 25.0 (Chicago,
Illinois).
Results
Out of 987 patients with severe AS undergoing TAVI, a
total of 258 (26%) patients had normal coronary arteries
based on coronary angiography (Figure 2). When defining
normal coronary arteries as absence of coronary calcifica-
tion on MDCT, 160 (16%) patients had normal coronary
arteries (Figure 2). Baseline characteristics are given in
Table 1 and procedural outcomes according to the updated
standardized end point definitions of the VARC-2 consen-
sus document in Table 2, respectively. In the coronary ath-
erosclerosis group, a total of 212 (29%) patients had prior
percutaneous coronary intervention (PCI) and a total of 139
(19%) patients prior coronary artery bypass grafting
(CABG). In 59 (8.1%) patients, concomitant PCI was per-
formed during TAVI and in 2 patients, PCI was performed
after TAVI.
At 12 months, a total of 143 patients had died, 104
patients from cardiovascular causes (Table 3). Although
mortality at 30 days was similar in the normal coronary
artery and the coronary atherosclerosis groups (3.1% vs
5.6%, p = 0.11), it was lower in those with normal coronary
arteries at 1 year (8.9% vs 17%, p = 0.003, Figure 3). Simi-
lar trends were observed when defining normal coronary
arteries by MDCT (Figure 3). In multivariable analysis, the
presence of normal coronary arteries on coronary angio-
gram independently predicted 1-year mortality (adjusted
HR 0.57, 95% CI 0.37 to 0.90, p = 0.02). Defining normal
Figure 1. Representative MDCT (A), echocardiography (B), and coronary
angiography (C) of a patient with severe aortic stenosis and concomitant cor-
onary atherosclerosis. Representative MDCT (D), echocardiography (E), and
coronary angiography (F) of a patient with severe aortic stenosis and normal
coronary arteries. MDCT=multi-detector computed tomography.
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coronary arteries by MDCT, normal coronary arteries were
not predictive for 1-year mortality (adjusted HR 0.78, 95%
CI 0.46 to 1.33, p = 0.37). Predictors of mortality by multi-
variable analysis are summarized in Table 4. When medica-
tion at discharge was incorporated individually into the
multivariable model, neither aspirin (adjusted HR 1.17, 95%
CI 0.67 to 2.02, p = 0.58), nor P2Y12 inhibitors (adjusted HR
0.86, 95% CI 0.52 to 1.40, p = 0.54), statins (adjusted HR
0.98, 95% CI 0.62 to 1.53, p = 0.92), beta blockers (adjusted
HR 1.18, 95% CI 0.78 to 1.78, p = 0.43), angiotensin
Figure 2. (A) Percentage of patients with severe aortic stenosis and normal coronary arteries or coronary atherosclerosis as defined by coronary angiography.




Variable Total (n=987) Coronary arteries p-value
Normal (n=258) Abnormal (n=729)
Age (years) 81.3 § 7.2 80 § 8.1 81.8 § 6.8 0.001
Women 488 (49%) 162 (63%) 326 (45%) <0.001
Body mass index (kg/m2) 26.8 § 4.9 27.2 § 5.6 26.7 § 4.6 0.17
Previous coronary bypass 139 (14%) 0 (0%) 139 (19%) <0.001
Previous percutaneous coronary intervention 212 (22%) 0 (0%) 212 (29%) <0.001
Peripheral artery disease 225 (23%) 40 (16%) 185 (25%) 0.001
Cerebrovascular disease 175 (18%) 33 (13%) 142 (20%) 0.02
Family history of coronary artery disease 102 (14%) 16 (8.9%) 86 (16%) 0.02
Arterial hypertension 785 (80%) 183 (71%) 602 (83%) <0.001
Type 2 diabetes mellitus 243 (25%) 48 (19%) 195 (27%) 0.009
Dyslipidemia 506 (51%) 120 (47%) 386 (53%) 0.08
Overweight or obesity 586 (59%) 153 (59%) 433 (59%) 1.0
Smoker 377 (38%) 80 (31%) 297 (41%) 0.006
Chronic obstructive pulmonary disease 154 (16%) 50 (19%) 104 (14%) 0.052
Estimated glomerular filtration rate (ml/min/1.73 m2) 56.7 § 21.2 58.9 § 22.8 55.9 § 20.6 0.053
Total cholesterol (mg/dl) 179.1 § 50.6 190.8 § 58.4 175.2 § 50.6 0.002
Low-density lipoprotein cholesterol (mg/dl) 101.6 § 43.2 109 § 46.7 97.3 § 42.8 0.02
High-density lipoprotein (mg/dl) 54.5 § 15.6 58.4 § 19.5 50.6 § 15.6 <0.001
Left ventricular ejection fraction (%) 54.6 § 13.5 57.2 § 12.6 53.7 § 13.6 <0.001
Mean transaortic pressure gradient (mmHg) 41.7 § 16.4 44.3 § 17.8 40.9 § 15.8 0.005
Aortic valve area (mm2) 0.75 § 0.21 0.74 § 0.22 0.75 § 0.21 0.43
Indexed aortic valve area, (mm2/m2) 0.41 § 0.12 0.41 § 0.12 0.41 § 0.12 0.68
Aortic valve Agatston score 2493 (1525-3649) 2326.0 (1477-3653) 2512.5 (1549-3654) 0.39
EuroSCORE II 4.2 (2.5-7.8) 3.2 (1.9-5.2) 4.7 (2.9-8.3) <0.001
STS Score 4.6 (3.0-6.9) 3.7 (2.6-5.7) 4.8 (3.2-7.3) <0.001
Medications at discharge
Aspirin 778 (83%) 198 (80%) 580 (85%) 0.13
P2Y12 inhibitor 760 (82%) 180 (73%) 580 (85%) <0.001
Statin 606 (65%) 111 (45%) 495 (72%) <0.001
Beta blocker 457 (49%) 110 (45%) 347 (51%) 0.06
Angiotensin converting enzyme
inhibitors/Angiotensin receptor blockers
593 (64%) 145 (59%) 448 (65%) 0.045
Calcium channel blocker 213 (23%) 40 (16%) 173 (25%) 0.005
Values are given as numbers and percentages, median (interquartile range), or mean (standard deviation).
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Table 2
Thirty-day procedural outcomes according to the criteria of the Valve Academic Research Consortium (VARC)-2.





Mortality 49 (5%) 8 (3.1%) 41 (5.6%) 0.11
Device success 850 (86%) 219 (85%) 631 (87%) 0.49
Myocardial infarction 12 (1.2%) 2 (0.8%) 10 (1.4%) 0.74
Stroke 43 (4.4%) 4 (1.6%) 39 (5.3%) 0.01
Major bleeding 70 (7.1%) 17 (6.6%) 53 (7.3%) 0.71
Acute kidney injury 127 (13%) 28 (11%) 99 (14%) 0.26
Major vascular complications 83 (8%) 20 (8%) 63 (9%) 0.66
Permanent pacemaker implantation 194 (20%) 41 (16%) 153 (21%) 0.08
Valve-related dysfunction requiring repeat procedure 16 (1.6%) 6 (2.3%) 10 (1.4%) 0.39
Values are given as numbers and percentages.
Table 3
Causes of death.
Causes of death Total (deaths=143) Coronary arteries
Normal (deaths=23) Abnormal (deaths=120)
Procedure-related 29 (20.3%) 5 (21.7%) 24 (20.0%)
Heart failure 30 (21%) 4 (17%) 26 (22%)
Myocardial infarction 5 (3.5%) 0 (0%) 5 (4.2%)
Cardiac arrest due to arrhythmia 2 (1.4%) 0 (0%) 2 (1.7%)
Cerebrovascular events 10 (7.0%) 1 (4.3%) 9 (7.5%)
Mesenteric ischemia 1 (0.7%) 1 (4.3%) 0 (0%)
Gastrointestinal bleeding 2 (1.4%) 0 (0%) 2 (1.7%)
Pulmonary disease 3 (2.1%) 0 (0%) 3 (2.5%)
Infection/systemic inflammatory response syndrome 20 (14%) 5 (22%) 15 (12%)
Renal failure 4 (2.7%) 2 (8.7%) 2 (1.7%)
Cancer 6 (4.2%) 2 (8.7%) 4 (3.3%)
Unknown (including cardiac arrest of unknown origin) 27 (19%) 3 (13%) 24 (20%)
Other 4 (2.8%) 0 (0%) 4 (3.3%)
Figure 3. (A) Kaplan-Meier survival curve of patients with severe aortic stenosis and normal coronary arteries or coronary atherosclerosis as defined by coro-
nary angiography. (B) Kaplan-Meier survival curve of patients with severe aortic stenosis and normal coronary arteries or coronary atherosclerosis as defined
by MDCT. MDCT =multi-detector computed tomography.
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converting enzyme inhibitors and/or angiotensin receptor
blockers (adjusted HR 1.00, 95% CI 0.65 to 1.54, p = 0.99),
and calcium channel blockers (adjusted HR 0.66, 95% CI
0.38 to 1.14, p = 0.13) were associated with 1-year mortality.
Although cardiovascular mortality at 30 days was similar
in the normal coronary artery and the coronary atherosclerosis
groups (2.7% vs 4.9%, p = 0.16), it was lower in those with
normal coronary arteries at 1 year (5.4% vs 12%, p = 0.001).
Similar results were observed when defining normal coronary
arteries byMDCT. In multivariable analysis, independent pre-
dictors of 1-year cardiovascular mortality were normal coro-
nary arteries based on coronary angiography (adjusted HR
0.45, 95% CI 0.26 to 0.79, p = 0.006), chronic obstructive pul-
monary disease (adjusted HR 1.69, 95% CI 1.06 to 2.70,
p = 0.001, p = 0.03) and estimated glomerular filtration rate
(adjusted HR 0.98, 95% CI 0.97 to 0.99, p <0.001). In the
sensitivity analysis defining normal coronary arteries by
MDCT, normal coronary arteries tended to be predictive for
1-year cardiovascular mortality (adjusted HR 0.51, 95% CI
0.26 to 1.02, p = 0.056).
Women had a higher prevalence of normal coronary arter-
ies as compared with men (p <0.001, Figure 2). Baseline
characteristics according to gender are given in Supplemen-
tary Table 1. In the coronary atherosclerosis group, besides a
similar prevalence of type 2 diabetes among women and men,
baseline differences between gender were consistent with
those of the whole TAVI cohort (Supplementary Table 2).
Women had a lower incidence of new permanent pacemaker
implantation (16% vs 24%, p = 0.001), while other procedural
outcomes according to the updated standardized end point
definitions of the VARC-2 consensus document were similar
in women and men. In men, 1-year mortality was 10% and
18% in the normal coronary artery and the coronary athero-
sclerosis groups (p = 0.09, Figure 4), and the corresponding
rates for cardiovascular mortality were 5.2% and 13%
(p = 0.02), respectively. In women, 1-year mortality was 8.0%
Figure 4. (A) Kaplan-Meier survival curve of men with severe aortic stenosis and normal coronary arteries or coronary atherosclerosis as defined by coronary
angiography. (B) Kaplan-Meier survival curve of women with severe aortic stenosis and normal coronary arteries or coronary atherosclerosis as defined by
coronary angiography.
Table 4
Predictors of 1-year mortality.
Variable Multivariable model 1 Multivariable model 2
Adjusted HR (95% CI) P-value Adjusted HR (95% CI) P-value
Age (years) 1.03 (1.00-1.06) 0.048 1.03 (1.00-1.06) 0.03
Female sex 0.86 (0.60-1.23) 0.40 0.81 (0.56-1.15) 0.23
Hypertension 1.23 (0.74-2.03) 0.41 1.29 (0.78-2.12) 0.32
Type 2 diabetes mellitus 1.14 (0.78-1.66) 0.51 1.16 (0.80-1.70) 0.43
Dyslipidemia 1.29 (0.92-1.82) 0.14 1.31 (0.93-1.85) 0.12
Obesity 0.85 (0.61-1.19) 0.34 0.84 (0.60-1.18) 0.32
Smoker 1.36 (0.96-1.93) 0.09 1.42 (1.00-2.00) 0.049
Peripheral arterial disease 1.52 (1.06-2.18) 0.02 1.58 (1.10-2.26) 0.01
Cerebrovascular disease 0.92 (0.61-1.41) 0.72 0.93 (0.61-1.43) 0.75
Chronic obstructive pulmonary disease 1.99 (1.34-2.94) 0.001 1.88 (1.27-2.77) 0.001
Estimated glomerular filtration rate (ml/min/1.73 m2) 0.98 (0.97-0.99) <0.001 0.98 (0.97-0.99) <0.001
Normal coronary arteries 0.57 (0.37-0.90) 0.02 0.78 (0.46-1.33) 0.37
Models were adjusted for all variables shown. Model 1: definition of normal coronary arteries based on coronary angiography. Model 2: definition of nor-
mal coronary arteries based on multi-detector computed tomography.
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and 15% in the normal coronary artery and the coronary ath-
erosclerosis groups (p = 0.04, Figure 4), and the correspond-
ing rates for cardiovascular mortality were 5.6% and 11%
(p = 0.07), respectively.
Discussion
This study demonstrates that patients with severe AS and
normal coronary arteries have a different risk profile and
improved outcomes after TAVI. Patients with normal coro-
nary arteries are younger, mostly women, and have a lower
burden of cardiovascular risk factors including hyperten-
sion, type 2 diabetes mellitus and smoking, although they
develop a virtually identical aortic valve calcification and
AS severity.
Coronary artery disease and calcific AS share common
risk factors and pathophysiological pathways and thus,
often coexist. Nevertheless, a quarter of patients with severe
AS undergoing TAVI in this study had normal coronary
arteries based on coronary angiography. The prevalence of
patients with normal coronary arteries observed in this
patient cohort is in line with previously reported data,4,5,9,19
and differences among studies are at least in part due to dif-
ferences in age, baseline risk, and nonuniform definitions of
coronary artery disease. The existence of a population with
severe calcific AS and completely normal coronary arteries
was confirmed by MDCT where 16% of patients displayed
coronary arteries devoid of any calcium accumulation.
Patients with normal coronary arteries were younger,
mostly women, and had a lower baseline risk. Despite these
differences in the presence of cardiovascular risk factors,
the severity of AS as assessed by echocardiography and
aortic valve calcium scoring was comparable among
patients with normal coronary arteries and those with coro-
nary atherosclerosis. Although AS and coronary artery dis-
ease are characterized by common pathophysiological
pathways such as inflammation, lipoprotein accumulation
and tissue calcification,20-24 this observation supports the
concept of distinct pathophysiological factors playing an
important role in the development of AS but not coronary
atherosclerosis. It is conceivable that these hypothetical
pathophysiological factors are triggered by a different set or
a different combination of cardiovascular risk factors as
could be observed in patients with normal versus athero-
sclerotic coronary arteries in this study. In line with this
interpretation, only weak to modest correlations between
calcific AS and coronary, carotid and aortic atherosclerosis
were observed in other studies;25-28 furthermore, choles-
terol-lowering therapies failed to halt the progression of AS
in randomized trials.29-31
Mortality rates of patients with severe AS and normal
coronary arteries tended to separate at 30 days after TAVI
from those with severe AS and coronary atherosclerosis,
with significant differences observed at 1 year. The absence
of coronary artery disease was associated with a 2-fold
lower mortality rate at 1 year after TAVI. Chronic obstruc-
tive pulmonary disease, peripheral arterial disease, and
impaired kidney function were independently associated
with mortality, while normal coronary arteries emerged as
independent negative predictor of 1-year mortality. The
existing data regarding the relationship of coronary artery
disease with mortality after TAVI are conflicting. In some
studies, severe coronary artery disease and incomplete
revascularization but not the presence of coronary artery
disease per se were related with worse outcomes after
TAVI.32,33 Patients with a Syntax Score >22 received less
complete revascularization and exhibited a higher risk of
cardiovascular events as compared with patients with a
lower Syntax Score.34 Other studies, however, failed to
show an association between coronary artery disease and
outcomes in TAVI patients.7,12,35 Our findings support the
concept that the extent and severity of coronary artery dis-
ease rather than the mere presence are related with worse
outcomes after TAVI. In line with this concept, this study
identified a lower risk population of mostly female patients
with severe AS and normal coronary arteries.
Sex-related baseline differences in patients with severe
AS undergoing TAVI have previously been reported. In
line with these studies,36,37 women with severe AS under-
going TAVI were older, less often smokers, and had higher
cholesterol levels and an higher left ventricular ejection
fraction,36,37 irrespective of the presence of coronary ath-
erosclerosis. In this study, sex-related baseline differences
in manifestations of atherosclerosis such as a lower preva-
lence of peripheral artery disease and cerebrovascular dis-
ease in women were observed in the coronary
atherosclerosis group. In contrast, this effect could not be
demonstrated in patients with normal coronary arteries.
This observation indicates that patients suffering from ath-
erosclerosis exhibit sex-related differences in the coexis-
tence of coronary, peripheral, and cerebral atherosclerosis.
Two thirds of patients with severe AS and normal coro-
nary arteries were women. We therefore speculate that
women may be protected from coronary atherosclerosis
although they are affected by AS. However, future studies
are needed to further investigate potential sex-related differ-
ences in disease expression and the underlying pathophysio-
logical mechanisms. Trends towards lower mortality rates
were observed in both women and men with normal coro-
nary arteries.
Some limitations need to be considered. The study includ-
ing a large cohort of patients with severe AS undergoing
TAVI is limited by its single-center observational design.
Further, although possible confounding variables were incor-
porated into the multivariable models, we cannot exclude
that unmeasured factors may have affected the results.
In conclusion, this contemporary study identified normal
coronary arteries as negative risk marker in patients with
severe AS undergoing TAVI. Patients with normal coronary
arteries were mostly women, had a different baseline risk
profile and a lower comorbidity burden. Despite these dif-
ferences in patient characteristics, the severity of AS and
aortic valve calcification were absolutely comparable.
Hence, coronary atherosclerosis should be incorporated
into the risk stratification of patients with severe AS and
personalized revascularization strategies need to be defined.
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